Complex Regional Pain Syndromes- Pipeline Insight, 2025

This “Complex regional pain syndromes- Pipeline Insight, 2025” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Complex regional pain syndromes pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Complex regional pain syndromes: Understanding

Complex regional pain syndromes: Overview

Complex regional pain syndrome (CRPS) is a term for a variety of clinical conditions characterised by chronic persistent pain and are subdivided into Type I and Type II CRPS. It is a condition that can develop after a limb trauma and appears mostly in one or more limbs. CRPS can be considered a regional post-traumatic neuropathic pain problem, and like other neuropathic pain disorders, symptoms are a disproportionate consequence of painful trauma or nerve lesion. CRPS affects approximately 26 out of every 100,000 people. It is more common in females than males, with a ratio of 3.5:1. CRPS can affect people of all ages, including children as young as three years old and adults as old as 75 years, but typically is most prevalent in the mid-thirties. CRPS Type I occurs in 5% of all traumatic injuries, with 91% of all CRPS cases occurring after surgery. CRPS can affect any part of the body, but occurs most often in the extremities. The wrist is most frequently affected after distal radial fractures. Complex regional pain syndrome can develop after different types of injuries, such as: Sprains and strains, surgeries, fractures, contusions, crush injuries, nerve lesions and Stroke. The exact cause of CRPS is unknown. It may be a disorder of the immunity system that affects the nervous system, producing inflammation of the nerves that control blood flow, sensation, and temperature. There are no specific tests to diagnose CRPS. Diagnosis is usually made during a physical examination based on signs consistent with the Budapest Criteria, a list of common signs and symptoms of CRPS developed by an international consensus panel. Specific tests can help provide clues, including a bone scan to detect any changes; and tests that measure differences in skin temperature, blood flow, and sweating between affected and unaffected limbs. In some cases, x-rays can show mineral loss in the bones. Magnetic resonance imaging (MRI) can also be used to determine if tissue changes typical of CRPS and specialized magnetic resonance neurography can be used to evaluate for specific nerve involvement. CRPS has no cure. Treatment is most effective when started early and focuses on relieving symptoms, slowing the progression of the disease, and helping sufferers cope with the pain and lead as healthy lives as possible.

'Complex regional pain syndromes- Pipeline Insight, 2025' report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Complex regional pain syndromes pipeline landscape is provided which includes the disease overview and Complex regional pain syndromes treatment guidelines. The assessment part of the report embraces, in depth Complex regional pain syndromes commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Complex regional pain syndromes collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Complex regional pain syndromes R&D. The therapies under development are focused on novel approaches to treat/improve Complex regional pain syndromes.

Complex regional pain syndromes Emerging Drugs Chapters

This segment of the Complex regional pain syndromes report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Complex regional pain syndromes Emerging Drugs

Soticlestat: Takeda

Soticlestat is a novel, first-in-class therapy designed and developed as a selective CH24H inhibitor with the potential to reduce seizure susceptibility and improve seizure control1. In February 2022, the Minister of Health, Labour and Welfare granted an orphan drug designation for soticlestat as a potential treatment for Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS), both of which are developmental epileptic encephalopathies (DEEs), designated as intractable diseases in Japan. The Breakthrough Award from Pharmaceutical Society of Japan recognizes Takeda’s research as contributing to the advancement of drug discovery research through the unique approaches taken to developing an innovative drug with a novel chemical structure. Takeda won this award for the first time in 9 years, marking its sixth win. Currently, the drug is in Phase II stage of Clinical trial evaluation for the treatment of Complex Regional Pain Syndrome.

TRP-8803: Tryp Therapeutics

TRP-8803, proprietary, psilocybin-based drug is manufactured exclusively for Tryp by Curia and Alcami and features a novel route of administration. Currently, the drug is in Preclinical stage of development for the treatment of Complex Regional Pain Syndrome.

Complex regional pain syndromes: Therapeutic Assessment

This segment of the report provides insights about the different Complex regional pain syndromes drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Complex regional pain syndromes

There are approx. 3+ key companies which are developing the therapies for Complex regional pain syndromes. The companies which have their Complex regional pain syndromes drug candidates in the most advanced stage, i.e. Phase II, Takeda.

Phases

The report covers around 3+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Complex regional pain syndromes pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Complex regional pain syndromes: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Complex regional pain syndromes therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Complex regional pain syndromes drugs.

Complex regional pain syndromes Report Insights

• Complex regional pain syndromes Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Complex regional pain syndromes Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Complex regional pain syndromes drugs?
• How many Complex regional pain syndromes drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Complex regional pain syndromes?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Complex regional pain syndromes therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Complex regional pain syndromes and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Takeda
• Tryp Therapeutics
• Soin Therapeutics

Key Products

• Soticlestat
• TRP-8803
• Low dose naltrexone

This product will be delivered within 1-3 business days.